105 related articles for article (PubMed ID: 31134726)
1. Outcomes of metastatic breast cancer patients in relationship to disease-free interval following primary treatment of localized disease; a pooled analysis of two clinical trials.
Abdel-Rahman O
Breast J; 2019 Sep; 25(5):823-828. PubMed ID: 31134726
[TBL] [Abstract][Full Text] [Related]
2. Impact of timeliness of adjuvant chemotherapy and radiotherapy on the outcomes of breast cancer; a pooled analysis of three clinical trials.
Abdel-Rahman O
Breast; 2018 Apr; 38():175-180. PubMed ID: 29432980
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial.
Abdel-Rahman O
Clin Transl Oncol; 2019 Feb; 21(2):239-245. PubMed ID: 29956074
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Baseline ALBI Score Among Patients With Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Mar; 18(1):e61-e68. PubMed ID: 30348618
[TBL] [Abstract][Full Text] [Related]
5. Bedtime misalignment and progression of breast cancer.
Hahm BJ; Jo B; Dhabhar FS; Palesh O; Aldridge-Gerry A; Bajestan SN; Neri E; Nouriani B; Spiegel D; Zeitzer JM
Chronobiol Int; 2014 Mar; 31(2):214-21. PubMed ID: 24156520
[TBL] [Abstract][Full Text] [Related]
6. Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies.
Abdel-Rahman O
Clin Transl Oncol; 2019 Jun; 21(6):810-816. PubMed ID: 30465184
[TBL] [Abstract][Full Text] [Related]
7. Impact of smoking history on the outcomes of women with early-stage breast cancer: a secondary analysis of a randomized study.
Abdel-Rahman O; Cheung WY
Med Oncol; 2018 Apr; 35(5):68. PubMed ID: 29644504
[TBL] [Abstract][Full Text] [Related]
8. Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease : An individual patient data analysis of three clinical trials.
Abdel-Rahman O
Strahlenther Onkol; 2019 Apr; 195(4):297-305. PubMed ID: 30069737
[TBL] [Abstract][Full Text] [Related]
9. Impact of Time to Start Systemic Therapy on the Outcomes of Patients with Metastatic Colorectal Cancer Treated with First Line FOLFOX Chemotherapy; a Patient-Level Pooled Analysis of Two Clinical Trials.
Oweira H; Giryes A; Mannhart M; Decker M; Abdel-Rahman O
Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):1069-1074. PubMed ID: 30099922
[TBL] [Abstract][Full Text] [Related]
10. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
[TBL] [Abstract][Full Text] [Related]
12. Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial.
Abdel-Rahman O; Cheung WY
Clin Genitourin Cancer; 2018 Dec; 16(6):466-472. PubMed ID: 30098982
[TBL] [Abstract][Full Text] [Related]
13. Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval.
Witteveen A; Kwast AB; Sonke GS; IJzerman MJ; Siesling S
PLoS One; 2015; 10(4):e0120832. PubMed ID: 25861031
[TBL] [Abstract][Full Text] [Related]
14. Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose.
Schneeweiss A; Hensel M; Sinn P; Khbeis T; Haas R; Bastert G; Ho AD
Ann Oncol; 2002 May; 13(5):679-88. PubMed ID: 12075735
[TBL] [Abstract][Full Text] [Related]
15. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
[TBL] [Abstract][Full Text] [Related]
16. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
[TBL] [Abstract][Full Text] [Related]
17. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.
Chang J; Clark GM; Allred DC; Mohsin S; Chamness G; Elledge RM
Cancer; 2003 Feb; 97(3):545-53. PubMed ID: 12548595
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V
BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347
[TBL] [Abstract][Full Text] [Related]
19. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
Mackey JR; Ramos-Vazquez M; Lipatov O; McCarthy N; Krasnozhon D; Semiglazov V; Manikhas A; Gelmon KA; Konecny GE; Webster M; Hegg R; Verma S; Gorbunova V; Abi Gerges D; Thireau F; Fung H; Simms L; Buyse M; Ibrahim A; Martin M
J Clin Oncol; 2015 Jan; 33(2):141-8. PubMed ID: 25185099
[TBL] [Abstract][Full Text] [Related]
20. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.
Kobayashi T; Ichiba T; Sakuyama T; Arakawa Y; Nagasaki E; Aiba K; Nogi H; Kawase K; Takeyama H; Toriumi Y; Uchida K; Kobayashi M; Kanehira C; Suzuki M; Ando N; Natori K; Kuraishi Y
Breast Cancer; 2012 Jul; 19(3):218-37. PubMed ID: 22532161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
